These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10861458)

  • 1. Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model.
    Hussey HJ; Tisdale MJ
    Int J Cancer; 2000 Jul; 87(1):95-100. PubMed ID: 10861458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a fluorinated pyrimidine on cachexia and tumour growth in murine cachexia models: relationship with a proteolysis inducing factor.
    Hussey HJ; Todorov PT; Field WN; Inagaki N; Tanaka Y; Ishitsuka H; Tisdale MJ
    Br J Cancer; 2000 Jul; 83(1):56-62. PubMed ID: 10883668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 inhibition and cardiovascular events.
    Pitt B; Pepine C; Willerson JT
    Circulation; 2002 Jul; 106(2):167-9. PubMed ID: 12105151
    [No Abstract]   [Full Text] [Related]  

  • 4. [The renal protective effect of selective cyclooxygenase-2 inhibitor on obstructive nephropathy].
    Zuo Y; Ma J; Gu Y; Yang H; Lin S
    Zhonghua Nei Ke Za Zhi; 2002 Dec; 41(12):825-8. PubMed ID: 12654237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced protection by melatonin and meloxicam combination in a middle cerebral artery occlusion model of acute ischemic stroke in rat.
    Gupta YK; Chaudhary G; Sinha K
    Can J Physiol Pharmacol; 2002 Mar; 80(3):210-7. PubMed ID: 11991232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
    Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
    Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis.
    Miyamoto K; Oka N; Kawasaki T; Miyake S; Yamamura T; Akiguchi I
    Muscle Nerve; 2002 Feb; 25(2):280-2. PubMed ID: 11870698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study.
    Altman R; Luciardi HL; Muntaner J; Del Rio F; Berman SG; Lopez R; Gonzalez C
    Circulation; 2002 Jul; 106(2):191-5. PubMed ID: 12105157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets.
    Girod V; Dapzol J; Bouvier M; Grélot L
    Neuropharmacology; 2002 Mar; 42(3):428-36. PubMed ID: 11897121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [From the COX-concept (Cyclooxygenase-2) to clinical gain. Meloxicam sets the standard. World-wide interactive video conference, London, 26 September 1997].
    Z Orthop Ihre Grenzgeb; 1997; 135(6 Suppl):1-4. PubMed ID: 9474258
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
    Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
    J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ischaemic colitis in a patient taking meloxicam.
    Garcia B; Ramaholimihaso F; Diebold MD; Cadiot G; Thiéfin G
    Lancet; 2001 Mar; 357(9257):690. PubMed ID: 11247558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effect of cyclo-oxygenase inhibitors with different isoform selectivity in lipopolysaccharide-induced preterm birth in mice.
    Lee PR; Kim SR; Jung BK; Kim KR; Chung JY; Won HS; Kim A
    Am J Obstet Gynecol; 2003 Jul; 189(1):261-6. PubMed ID: 12861172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials.
    Schoenfeld P
    Am J Med; 1999 Dec; 107(6A):48S-54S. PubMed ID: 10628593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
    Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
    Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of glandular stomach carcinogenesis through duodenogastric reflux in rats by a COX-2 inhibitor.
    Oba M; Miwa K; Fujimura T; Harada S; Sasaki S; Hattori T
    Int J Cancer; 2008 Oct; 123(7):1491-8. PubMed ID: 18646190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meloxicam inhibits the growth of colorectal cancer cells.
    Goldman AP; Williams CS; Sheng H; Lamps LW; Williams VP; Pairet M; Morrow JD; DuBois RN
    Carcinogenesis; 1998 Dec; 19(12):2195-9. PubMed ID: 9886578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferential COX-2 inhibitor, meloxicam, compromises renal perfusion in euvolemic and hypovolemic rats.
    Birck R; Krzossok S; Knoll T; Braun C; van Der Woude FJ; Rohmeiss P
    Exp Nephrol; 2000; 8(3):173-80. PubMed ID: 10810234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of an anti-inflammatory therapy and its withdrawal on the progression of experimental periodontitis in rats.
    Gurgel BC; Duarte PM; Nociti FH; Sallum EA; Casati MZ; Sallum AW; de Toledo S
    J Periodontol; 2004 Dec; 75(12):1613-8. PubMed ID: 15732862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
    Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
    Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.